^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

High NLR

11ms
Prognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study. (PubMed, J Thorac Dis)
NLR and LDH may be used as prognostic biomarkers patients with SCLC treated with PD-1/PD-L1 inhibitors. The promising clinical application of NLR and LDH in efficacy prognostic indicators and beneficiary selection for SCLC immunotherapy is highlighted.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
High NLR • High MLR
11ms
Prognostic Value of Blood-Based Inflammatory Markers in Cancer Patients Receiving Immune Checkpoint Inhibitors. (PubMed, Cancers (Basel))
Our findings confirm the prognostic utility of several inflammatory biomarkers in patients with cancer receiving ICIs, highlighting their potential for treatment stratification. Further studies are necessary to standardize cut-off values and validate these findings across broader, more diverse populations.
Journal • Checkpoint inhibition • IO biomarker
|
CRP (C-reactive protein)
|
High NLR • Albumin-L
11ms
Impact of the Inflammatory Burden Index on Prognosis After Hepatectomy for Colorectal Liver Metastasis. (PubMed, Am Surg)
The IBI was a strong predictor for both short- and long-term outcomes in patients who underwent hepatic resection for CRLM.
Journal
|
CRP (C-reactive protein)
|
High NLR
1year
Can some inflammatory parameters predict the survival of patients with malignant pleural effusion? (PubMed, Turk Gogus Kalp Damar Cerrahisi Derg)
Poor prognostic factors that were found to be statistically significant were high CRP (p=0.001), high NLR (p=0.001), high PLR (p=0.02), and high serum LDH-to-pleural LDH ratio (p=0.04). Some serum inflammatory markers, including high CRP, high NLR, high PLR, and high serum LDH-to-pleural LDH ratio, can be a simple and inexpensive method in predicting prognosis in patients with MPE.
Journal • Pleural effusion
|
CRP (C-reactive protein)
|
High NLR • High PLR
1year
Association of inflammatory blood markers and pathological complete response in HER2-positive breast cancer: a retrospective single-center cohort study. (PubMed, Front Immunol)
IBMs play a diverse predictive role in pCR in HER2-positive breast cancer stratified by neoadjuvant regimens. The combination of high MLR and high NLR enabled better identification of patients with poor responses to anti-HER2 therapy than high MLR or NLR alone.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • EGFR positive • High NLR • High MLR
1year
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients. (PubMed, Front Oncol)
We retrospectively analyzed the outcomes of combination therapy, including nivolumab plus ipilimumab or chemotherapy plus anti-programmed cell death 1 (PD-1) antibodies in our institute to identify biomarkers...In multivariable analysis, albumin level was significantly correlated with PFS in the cisplatin plus 5-fluorouracil (CF) plus pembrolizumab group...In chemotherapy combined with ICIs, NLR before the treatment was not associated with treatment efficacy, suggesting combination chemotherapy may be beneficial for EC patients with high NLR. NLR may be an indicator of immunocompetence in anti-tumor immunity and a convenient predictive biomarker for selecting appropriate treatments including ICIs.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CRP (C-reactive protein)
|
High NLR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • 5-fluorouracil
1year
Adherence to Mediterranean Diet and Biomarkers of Redox Balance and Inflammation in Old Patients Hospitalized in Internal Medicine. (PubMed, Nutrients)
Old patients admitted to internal medicine wards with low adherence to the MD display unfavorable profiles of the circulating markers of redox balance and inflammation. It is conceivable that such effects on redox balance can be linked to the high polyphenol content of MD. This study supports the rationale for intervention trials that attest to the effectiveness of MD as a nutritional strategy for disease prevention.
Journal • Adherence
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
High NLR
1year
Analysis of Correlation between Blood Inflammation Indicators in Peripheral Blood and Prognosis of Patients with Multiple Myeloma. (PubMed, Clin Lab)
High NLR and low LMR counts of peripheral blood suggest a poor prognosis; NLR and LMR may be prognostic indicators in MM patients.
Journal
|
B2M (Beta-2-microglobulin)
|
High NLR
1year
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy. (PubMed, Br J Haematol)
Interestingly, the reduction in JAK2 VAF from baseline was linearly associated with the reduction in NLR. Patients who failed Phl-O at 12 months had characteristics that distinguished them from responders, including very high NLR and resistance to cross-over to 100 μg Ropeg every 2 weeks suggesting higher escalated doses of Ropeg. In conclusion, the study provides evidence that NLR can serve as a valuable biomarker to assess and guide treatment with Ropeg in the early stage of low-risk PV patients.
Journal
|
JAK2 (Janus kinase 2)
|
High NLR • JAK2 V617F
|
Besremi (ropeginterferon alfa-2b-njft)
1year
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study. (PubMed, Eur J Cancer)
Patients with (g)HRD PV-associated PDAC had longer OS than those with (s)HRD PV. Olaparib use beyond the scope of the POLO trial was associated with poor outcomes.
Retrospective data • Journal • Real-world evidence • BRCA Biomarker • PARP Biomarker • Real-world
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
HRD • High NLR
|
Lynparza (olaparib)
1year
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms. (PubMed, Ann Hematol)
Besides previous thrombosis, most important factor associated with development of arterial thrombosis is NLR ≥ 4.5 and for venous PLR ≥ 500. Our results revealed that NLR ≥ 4.5 could be used as additional marker to distinguish ET from prePMF.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
High NLR
over1year
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer. (PubMed, Int J Clin Oncol)
NLR at EOT with CDK4/6 inhibitors is a significant and independent prognostic marker for patients with ER-positive HER2-negative advanced breast cancer.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • EGFR positive • High NLR • ER positive + HER-2 negative • High ALC • HER-2 negative + ER positive
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • fulvestrant